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Background : Cardiovascular system was the second most common organ system affected by COVID-19 and many 
cases of COVID-19 reported cardiac injury. The goal of this study was to explore the correlation of cardiac injury 
with mortality in patients with COVID-19.
Objectives : This study aimed to explore the incidence of cardiac injury in patient with COVID-19, analyze the 
correlation between cardiac injury, represented by cardiac biomarker elevation, and mortality in COVID-19 
patients, and search the feasible mechanism of cardiac injury in COVID-19 patients.
Methods : We performed a systematic review and meta-analysis study. The relevant studies were identified 
through scientific electronic databases such as PubMed, Cochrane, and ScienceDirect up to August 2020. The 
study quality assessment was conducted using the GRADE approach. The pooled odds ratio (OR) and 95% 
confidence interval (CI) were estimated using the random-effects model.   
Results: A total of 10 studies involving 2619 patients were included in the meta-analysis. The incidence of cardiac 
injury in COVID-19 patients was 28.5%. The all-cause mortality was significantly higher in patients with cardiac 
injury (52.8% vs. 13.1%; OR = 13.78; 95% CI = 7.22-26.32; I 2 = 88%; Z= 7.95; P < 0.00001).
Conclusion: In COVID-19 patients, heart failure is associated with higher mortality. As a major aspect in the risk 






 COVID-19 has been an emerging global health issue. The 
numbers of COVID-19 patients continue to increase, with 25 million 
confirmed cases from January to August 2020.1 In Indonesia, over 170 
thousand confirmed cases were reported at the end of August 2020. 
The case fatality rate in Indonesia was 4.2%, higher than the global 
average case fatality rate, which is 3.4%.1,2 On August 31, 2020, 
Indonesia was the runner-up for the mortality rate caused by COVID-19 
in Southeast Asia, under the Philippines. The mortality rate in Indone-
sia was 28 per million, while the Philippines was 33.9 per million.3 Due 
to its high mortality rate, the identification of predictors of progression 
towards fatal disease is urgently needed, as we are still encountering 
difficulties in how to identify patient at risk for severe disease early in 
the course of COVID-19.4
 Progression of COVID-19 consists of three stages: early 
infection, pulmonary, and severe hyper inflammation.5 Virus infiltrates 
and proliferates during the early infection phase, induce activation of 
monocytes and macrophages. Pulmonary damage induces hypoxemia 
and cardiovascular stress as secondary organ damage. 
The cardiovascular system was the second most common organ system 
affected by COVID-19 after the lungs. Among deceased COVID-19 
confirmed cases in Indonesia, 7.6% of patients had cardiovascular 
disease.1 Several manifestations of cardiac injury in COVID-19 are 
arrhythmias, acute coronary syndrome, heart failure, cardiogenic 
shock, and thromboembolism.5-7 Elevation of cardiac troponin is a 
surrogate of myocardial injury. The goal of this systematic review and 
meta-analysis was to investigate the association of heart injury with 
mortality in patients with COVID-19.
2. Methods
2.1. Search strategy
 In this systematic review and meta-analysis study, we collect-
ed relevant studies from the electronic scientific databases such as 
PubMed, Cochrane, and ScienceDirect up to August 10, 2020. The 
keywords were “myocardial damage” or “myocardial injury” or “cardiac 
injury” or “myocarditis” or “myocardium” and “coronavirus” or 
“COVID” or “COVID-19” or “SARS-CoV2” or “mortality” or “death.” We 
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2.2. Selection criteria
 Cohort studies, case-control studies or case series that 
examined the effects of heart injury on mortality were screened. 
Inclusion criteria were: (1) cohort, case-control, or case series study; 
(2) study included all patients with confirmed COVID-19 using PCR; 
(3) available data of the presence of cardiac injury, which was defined 
as an increased troponin level; (4) available data of mortality in cardiac 
injury patients compared to mortality in non-cardiac injury patients. We 
exclude papers that only include severe COVID-19 patients, no data of 
increased cardiac marker, unpublished studies, and duplicate articles. 
We conducted a study quality assessment using the GRADE approach.8
2.3. Data collection
 Papers were evaluated by two authors separately. Standard-
ized types were created, including authors, year of study, design of 
study, cut-off point for high sensitivity cardiac troponin I (hs-cTn), 
cut-off point for troponin, cardiac injury, and mortality. The cardiac 
injury was defined as the elevation of hs-cTn or troponin level of more 
than its 99th percentile above the upper reference limit, disregarding 
the electrocardiography and echocardiography variables. The primary 
outcome was all-cause mortality.
2.4. Statistical analysis
 With the random effects model, the odds ratio and 95 
percent confidence interval (CI) were calculated and heterogeneity was 
tested with RevMan 5.44 using the I2 test.9 The findings of the I2 
statistics were interpreted as 25%, 50% and 75%, reflecting low, 
moderate and high heterogeneity. 
moderate and high heterogeneity. Funnel plots and the Harbord test 
was used to test publication bias. Funnel plot asymmetry indicates the 
presence of publication bias, and the Harbord test p-value < 0.05 
indicates a small-study effect, which suggests the presence of publica-
tion bias.
3. Results
 We identified 818 papers, and 814 remained after the 
removal of duplicates. We screened the title or abstracts then excluded 
755 papers. Sixty-one papers were evaluated for eligibility criteria. We 
excluded 51 papers because of several reasons: 1) only included severe 
COVID-19 patients (n=10), 2) no data of increased cardiac marker 
(n=7), 3) no data of cardiac injury mortality (n=14), 4) unpublished 
studies (n=9), 5) included not only confirmed case but also probable 
case (n=10), 6) used myoglobin as biomarker assessment (n=1), 7) 
included patients with significant comorbidities (n=10). Finally, we 
included 10 studies in this meta-analysis (Figure 1). 
 Table 1 displays the baseline features of the included studies. 
All the studies used were observational cohort studies. Ten studies from 
Turkey, China, the United States, and Spain with 2038 patients were 
included in this meta-analysis. The incidence of cardiac injury in 
COVID-19 patients was 28.5%. The all-cause mortality was significantly 
higher in patients with cardiac injury (52.8% vs. 13.1%; OR = 13.78; 
95% CI = 7.22-26.32; I 2 = 88%; Z= 7.95; P < 0.00001) as shown in 
figure 2. The presence of significant heterogeneity was revealed by I2 
value of 81%. The existence of publication bias was indicated by the 
asymmetric funnel plot (Figure 3) and the Harbord test result (p = 
0.031) (Supplementary figure 1).
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Figure. 1 PRISMA study flow diagram
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Figure.2 Forrest plot : Cardiac injury associated with higher mortality in COVID-19 patients. The squares and horizontal lines 
correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the study-specific weight. The diamond 
represents the pooled results of OR and 95% CI.
4. Discussion
 This meta-analysis revealed that the incidence of cardiac 
injury among COVID-19 patients was very high (28.5%). Cardiac 
injury, proven by the elevated troponin levels, is significantly associated 
with higher all-cause mortality. COVID-19 is caused by the infection of 
SARS-CoV-2, the virus that infects the host via ACE2 receptors. The 
ACE2 receptors can be found in type II pneumocyte lung epithelium, 
myocardium, endothelium, gastrointestinal tract, bone marrow, kidney, 
and spleen. There are three stages in COVID-19 infection: stage I (initial 
viral infection), stage II (acute respiratory distress syndrome), and 
stage III (hyperinflammatory state).10 Besides causing severe acute 
respiratory syndrome, SARS-CoV-2 can also induce cardiac injury. The 
pathogenic mechanism of cardiac injury in COVID-19 is still unclear. 
Several possible mechanisms of cardiac injury in COVID-19 patients 
are: 1) direct myocardial injury; 2) microvascular injury; 3) systemic 
inflammation; 4) oxygen demand and supply mismatch in myocardium 
due to lung damage; and 5) acute coronary event due to plaque rupture 
induced by inflammation.10,11
 
 Direct myocardial injury can occur because of fulminant 
myocarditis mediated by the ACE2 receptors on the myocardium.10 The 
minimally invasive autopsy was performed on patients who died from 
COVID-19 in China. The results showed that the nucleic acid of 
SARS-CoV-2 was found not only in the lungs but also in the heart, blood 
vessels, liver, and other organs.12 Microvascular injury is caused by 
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Figure 3. Funnel plot asymmetry indicates the presence of publication bias. Each circle denotes an independent study for the indicated 
association. Log[OR] is the natural logarithm of OR. The horizontal line represents the mean effect size. OR: odds ratio; SE: standard 
error.
 
coagulation and fibrinolytic disruption. More than 70% of patients who 
died from COVID-19 met the DIC criteria.13 Infection and sepsis are 
associated with immune complexes that lead to a hypercoagulable 
state, similar to DIC. Hypercoagulable state causes microthrombus 
formation and microvascular dysfunction, which is thought to cause 
cardiac injury.10
 
 The COVID-19 infection causes the elevation in inflammatory 
biomarkers and cytokines level, including IL-6, CRP, TNF-alpha, IL-2R, 
and ferritin, resulting in the systemic inflammatory response. The 
patient who reaches stage III has severe COVID-19 manifestation due to 
cytokine storm. In this stage, patients have various clinical presentation 
form of multi-organ dysfunction to death.10 The increased cytokine level 
can also activate inflammatory cells in atherosclerotic plaques. When 
activated, intraplaque inflammatory cells will up-regulate host response 
proteins, including metalloproteinases and peptidases. This condition 
may lead to oxidative stress and extracellular matrix component 
degradation, contributing to plaque destabilization. The plaque will be 
more prone to rupture, exposing the thrombogenic components in the 
subendothelial layer, leading to acute thrombus formation.16 Severe 
COVID-19 infection can reduce oxygen delivery to the myocardium 
through systemic hypoxemia and vasoconstriction mechanisms. Severe 
infection also increases oxygen demand. The oxygen demand and 
supply mismatch can induce myocardial ischemia in patients with 
underlying coronary artery disease.14
 Abnormal electrocardiography in COVID-19 patients may 
vary, including tachycardia, atrioventricular or interventricular block, 
ST-T changes, QT-interval prolongation, and malignant arrhythmias. 
Viral infection causes cytokine storm, hypoxemia, and hypercoagulabili-
ty state, leading to hypoxemia, myocardial tissue damage, and arrhyth-
mias. Arrhythmias can also occur secondary to COVID-19 medical 
therapy. Fever may increase sympathetic tone and leads to tachyar-
rhythmias in COVID-19 patients without heart disease. Fever may 
induce ventricular fibrillation in COVID-19 patients with underlying 
heart disease.15
 The limitation of this study was the presence of heterogeneity 
because COVID-19 is a relatively new disease. The treatment strategies 
were widely varied among several centers. There was also publication 
bias indicated by the asymmetric funnel plot and the Harbord test 
result. The included studies in our meta-analysis also did not specify 
whether the elevation in troponin level was due to myocarditis, myocar-
dial infarction, or other mechanisms. Therefore, the elevated troponin 




 Cardiac injury is associated with a higher mortality rate in 
COVID-19 patients. Therefore, cardiac injury should be considered as 
an important variable in the risk stratification for mortality in 
COVID-19. Elevated troponin, which represents cardiac injury, might be 
the potential marker of poor prognosis in COVID-19.
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